|Quantity Discounts||1 - 2|
|3 - 4|
|5 - 6|
|7 - 9|
|10 - 9999|
Brexit and Life Sciences Companies
Your international drug and device business is at a crossroads known as ‘Brexit’ — the imminent departure of the United Kingdom (U.K.) from the European Union (EU).
Terms of departure are to be negotiated over the coming two years. What will the final outcome look like? Will there be a deal for duty-free movement of goods among nations? Or will punitive tariffs ensue? These are just a few of the questions to which you need answers — ASAP.
FDAnews has invited global drug-and-device expert Michael Burke Esq. to share his crystal ball. As law his firm’s in-house expert on drugs and devices as well as a specialist in cross-border international trade, Mr. Burke is uniquely qualified.
Get set for an information-fest. In 90 fast-paced minutes, Mr. Burke will cover the make-or-break questions, including:
This top-level Web presentation is aimed at senior officials in your organization — President, Vice President, CEO/COO/CFO — as well as executives with responsibilities in:
Michael Burke Esq., Partner, Arnall Golden Gregory LLP
Washington lawyer Michael Burke has dual qualifications as a guide to the post-Brexit world: He is his firm’s in-house expert on drugs and devices; and a specialist in cross-border international trade. His particular focus, Ireland, is the one remaining English-speaking nation in a post-Brexit EU. Mr. Burke counsels transnational clients on anti-boycott regulations, export controls, economic sanctions and the Foreign Corrupt Practices Act; and represents them before the Justice Dept., Treasury Office of Foreign Assets Control, State Dept. Office of Defense Trade Controls, and Commerce Dept. Bureau of Industry and Security. He is author of the Irish Export Insights blog, https://irishexportinsights.com/ and co-editor and co-author of The Corporate Counsel’s Guide to Doing Business in China (Thomson Reuters).
Copyright ©2018. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing